SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending due to its collaboration with Nokia to deliver AI-optimized data center networking solutions, which the community believes could redefine its role in the AI supply chain. Bullish sentiment is growing as investors discuss the potential for margin expansion and a stock rerating, though some remain cautious due to the company's historical compliance issues. The community questions whether this is a true breakout or just another AI hype spike.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Fueled by a new CEO and co-founders rejoining the board, Opendoor (OPEN) is trending as investors speculate on the company's new direction in real estate technology. The community is actively discussing the potential for a short squeeze, with many expressing bullish sentiment and dismissing negative opinions. Some traders are drawing comparisons to previous meme stock rallies, while others focus on the company's revenue and growth potential.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a recent surge in price and volume, fueled by excitement around its AI-powered visual search technology and anticipation for upcoming earnings. Community members are actively discussing the potential for a short squeeze and the company's undervalued status compared to its peers, with some pointing to a possible stop loss hunt during after hours. The stock's connection to Microsoft and Google is also a key talking point, as investors weigh the potential impact of these partnerships.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its position as the premier memecoin on the Bitcoin network, emphasizing its fair launch and strong community. Discussions highlight its potential to onboard new users to Bitcoin and its unique position within the Runes and Ordinals ecosystem. Some community members are comparing it to Dogecoin, suggesting it may be the next big meme coin.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as the company prices a public offering, while the community debates the implications of the raise and anticipates potential acquisitions or contract news. Bullish sentiment remains, with many pointing to the company's strategic positioning in the drone and counter-drone technology space, particularly amid rising geopolitical tensions and increased defense spending. Discussions also highlight Ondas's presence at upcoming conferences and potential involvement in European defense initiatives.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet's $GOOGL is trending as investors digest a favorable antitrust ruling and anticipate further gains driven by AI initiatives. Community discussions focus on the stock's overbought conditions and potential for a pullback, while analysts raise price targets amid positive sentiment. Broader AI and cloud computing trends are also contributing to the conversation around Alphabet's future growth prospects.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending due to recent price action and community speculation about a potential short squeeze, buyout, or partnership, with discussions revolving around high short interest and potential FDA approval of Belapectin for liver cirrhosis. The community is closely monitoring dark pool activity and institutional buying, while some are discussing potential price targets and the possibility of a significant market cap increase. Community members are debating the strength of the science, potential partnership deals, and possible actions by management to enhance shareholder value.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation around a potential acquisition bid from Paramount Skydance, with the rumor driving significant trading volume and a jump in share price. The community is actively discussing the possible terms of a deal and the potential for a bidding war, with some believing WBD's assets are undervalued. This news arrives as WBD is planning to split into two separate publicly traded companies, adding another layer of complexity to the situation.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna's recent IPO is driving significant interest, with community members actively discussing its valuation relative to competitors like Affirm and potential for long-term growth. ARK Invest's substantial purchase of KLAR shares has further fueled the conversation. Some traders are wary of employee share dumping and potential overvaluation, while others point to Klarna's large user base and expansion plans as reasons for optimism.

BGSF, Inc. engages in providing consulting, managed services, and professional workforce solutions. It operates through the Property Management and Professional segments. The Property Management segment offers office and maintenance talent in 38 states and D.C. to property management companies responsible for the apartment communities’ and commercial buildings’ day-to-day operations. The Professional segment is involved with specialized talent and business consultants for information technology, managed services, finance, accounting, legal and human resource. The company was founded on August 27, 2007, and is headquartered in Plano, TX.

BGSF Inc

$BGSF is trending due to news of a special dividend, with the community drawing comparisons to similar plays like $SOGP and anticipating a multi-day run. Bullish sentiment is fueled by the significant dividend payout relative to the stock price and a relatively small float. Some traders are wary of a potential shakeout by shorts given the company's low float.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug Administration granted Fast Track designation to its experimental treatment for alopecia areata.The drug, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody being tested in a Phase 2 trial for alopecia areata (AA), an autoimmune disorder that causes hair loss.&nbsp;The Fast Track status is intended to speed development of therapies that address serious conditions and unmet medical needs."The Fast Track designation granted by the FDA recognizes the seriousness of AA and the significant current unmet medical need while underscoring bempikibart's potential as a novel, differentiated therapy," said Q32 Bio Chief Executive Jodie Morrison in a statement.Bempikibart is designed to re-regulate immune function by blocking IL-7 and TSLP signaling pathways, key components in autoimmune activity.&nbsp;The company recently began dosing patients in both an open-label extension and Part B of its SIGNAL-AA trial following encouraging early results.The FDA designation allows for more frequent meetings with the agency, eligibility for priority review, and the possibility of accelerated approval, subject to clinical results.On Stocktwits, 24-hour message volume for Regulus jumped by 1,600% amid bullish sentiment.Some users highlighted the stock’s low float and recent FDA news as drivers for a potential swing trade, while others noted that the therapy itself — bempikibart — is making steady clinical progress.&nbsp;<stembedurl>https://stocktwits.com/onlyfactshere/message/613083538</stembedurl>One user pointed to the Fast Track status as a key catalyst, potentially accelerating development timelines for a treatment area with few approved options.&nbsp;<stembedurl>https://stocktwits.com/ALOSETE/message/613089756</stembedurl>Still, some cautioned that despite promising Phase 2 data, the company’s limited cash runway — estimated at about five quarters — underscores the inherent risks of biotech investing.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/613078123</stembedurl>Shares of Q32 Bio have declined 1.9% year-to-date, underperforming the Nasdaq, which is down 1.6%, but faring better than the Dow and S&amp;P 500, which have fallen 4.1% and 5.1%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.

Equity

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio to Participate in Upcoming March Investor Conferences Q32 Bio to Participate in Upcoming March Investor Conferences PR Newswire WALTHAM, Mass., Feb. 26, 2025 WALTHAM, Mass., Feb. 26, 2025...

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in...

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference PR Newswire WALTHAM...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of its lead candidate, bempikibart (ADX-914).&nbsp;The clinical-stage biotech company is under heavy selling pressure, with retail sentiment turning ‘extremely bearish’ on Stocktwits amid a spike in message volume.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QTTB_sentiment_and_message_volume_on_Dec_11_5dea79b168.png" alt="QTTB sentiment and message volume on Dec 11.png" width="1318" height="324"><figcaption>QTTB sentiment and message volume on Dec 11 as of 8:30 am ET | source: Stocktwits</figcaption></figure>The SIGNAL-AA trial for alopecia areata showed “encouraging” clinical activity, with a mean reduction of 16% in the Severity of Alopecia Tool (SALT) score for bempikibart recipients versus 2% in the placebo group at 24 weeks.&nbsp;However, only 9% of bempikibart patients achieved SALT-20, compared to none in the placebo group.Meanwhile, the SIGNAL-AD trial for atopic dermatitis failed to meet its primary endpoint in Part B, with patients receiving bempikibart showing a 74% improvement in the Eczema Area and Severity Index at 14 weeks, compared to 76% in the placebo group.&nbsp;CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better.The mixed results prompted a series of downgrades:• Wells Fargo cut its rating to ‘Equal Weight’ from ‘Overweight’ and slashed its price target to $16 from $95, citing disappointing atopic dermatitis results and concerns over Q32’s cash needs.• Leerink lowered its rating to ‘Market Perform’ from ‘Outperform’, with a price target of $9, down from $68. The firm removed atopic dermatitis value from its model and noted uncertainty around alopecia areata progression.• Raymond James downgraded Q32 Bio to ‘Outperform’ from ‘Strong Buy’, with its price target falling to $22 from $90. Analyst Steven Seedhouse highlighted underestimated market reaction but acknowledged the potential of the IL7R-4 mechanism.• Oppenheimer reduced its price target to $20 from $80 while maintaining an ‘Outperform’ rating, citing the alopecia opportunity’s potential despite setbacks in atopic dermatitis.Despite the sharp decline, QTTB shares remain up over 120% year-to-date.&nbsp;However, near-term sentiment and confidence in the stock have been severely dented, with investors awaiting further clarity on the drug’s development plans.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Q32 Bio Stock Plunges After Analyst Downgrades, Price-Target Slashes Over Alopecia Data: Retail Confidence Drops

CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing...

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov...

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 Q32 Bio to Present Tissue-Targeted...

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Aug. 29, 2024 WALTHAM, Mass., Aug. 29...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Immunovant (IMVT) and Q32 Bio (QTTB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW Research Report), Immunovant (IMVT R...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

QTTB
Q32 Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QTTB News

QTTB Q32 Bio Inc.